Secondary Logo

Share this article on:

Whole-genome sequencing of bacterial sexually transmitted infections: implications for clinicians

Seth-Smith, Helena M.B.; Thomson, Nicholas R.

Current Opinion in Infectious Diseases: February 2013 - Volume 26 - Issue 1 - p 90–98
doi: 10.1097/QCO.0b013e32835c2159
SEXUALLY TRANSMITTED DISEASES AND URINARY TRACT INFECTIONS: Edited by Phillip Hay and John A. White

Purpose of review Increasingly, genomics is being used to answer detailed clinical questions. Although genome analysis of bacterial sexually transmitted infections (STIs) lags far behind that of many other bacterial pathogens, genomics can reveal previously inaccessible aspects of pathogen biology.

Recent findings Comparative genomic studies on the most common bacterial STI, chlamydia, have revolutionized our understanding of this intracellular bacterium, demonstrating that it undergoes extensive recombination and that the traditional typing schemes can be misleading. Genome projects can also help us to understand the recently observed phenomenon of ‘diagnostic escape’ seen in both Chlamydia trachomatis and Neisseria gonorrhoeae.

Summary The routine use of genomics in clinical settings is becoming a reality. For STIs, a primary requirement is an understanding of the diversity of circulating strains and how they change over time. This can help to inform future studies and allow us to address real clinical issues such as outbreak identification, global spread of successful clones and antimicrobial resistance monitoring.

Pathogen Genomics, The Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK

Correspondence to Nicholas R. Thomson, Pathogen Genomics, The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK. Tel: +44 1223 494740; fax: +44 1223 494919; e-mail: nrt@sanger.ac.uk

Back to Top | Article Outline

INTRODUCTION

Chlamydia, gonorrhoea and syphilis are the three most common bacterial sexually transmitted infections (STIs) worldwide [1], caused by Chlamydia trachomatis, Neisseria gonorrhoeae and Treponema pallidum subsp. pallidum (T. p. pallidum), respectively. Of these infections, chlamydia is the most commonly diagnosed in the UK, USA and globally, while there has been a recent rise in the global incidence of gonorrhoea, and in syphilis cases in the UK and USA [1–3] (Table 1 [1–9]). This review focusses on how genomics can inform our understanding of these pathogens evolutionarily, clinically and epidemiologically.

Table 1

Table 1

Back to Top | Article Outline

CLINICAL OUTCOMES

Chlamydia and gonorrhoea share some aspects of their disease outcomes, as both are able to cause pelvic inflammatory disease and epithelial scarring which can lead to infertility, although they can also be asymptomatic. However, N. gonorrhoeae infections tend to be more acute, with symptoms including purulent discharge and acute local inflammation; in rare cases when the bacterium disseminates through the host, rashes and septic arthritis can occur. An invasive biovar of C. trachomatis causes lymphogranuloma venereum (LGV) which exists as a genital ulcer disease in many resource-poor locations and was seen recently as an outbreak amongst men who have sex with men (MSM) associated with proctitis. C. trachomatis is also the leading cause of infectious blindness (trachoma [10], which will not be discussed in detail here). Early signs of syphilis are also localized to the genital area, usually characterized by a chancre or sore, yet within a few weeks the disease can move to a secondary stage characterized by a rash on one or more areas of the body. Without treatment a tertiary stage can develop, even after a latent period of many years, resulting in damage to internal organs including the brain, nerves, and cardiovascular system, which can lead to a range of complications, neurological disorders and ultimately death. T. p. pallidum can also pass through the placenta, causing congenital syphilis leading to foetal developmental problems or stillbirth. All three bacteria have been implicated in preterm birth.

Box 1

Box 1

Back to Top | Article Outline

CELL BIOLOGY OF BACTERIAL SEXUALLY TRANSMITTED INFECTION PATHOGENS

C. trachomatis, N. gonorrhoeae and T. p. pallidum are all human-restricted pathogens, despite having closely related species that are less restricted in their host range. All are Gram-negative, yet belong to different bacterial phyla (Fig. 1 [11]) and infect the host in very different ways. C. trachomatis strains are obligate intracellular bacteria with a unique biphasic developmental cycle. Small, infectious elementary bodies are endocytosed into the host cell, sequestered into specialized inclusion vesicles where they differentiate into reticular bodies. This metabolically active form replicates until the inclusion fills the host cell, when the reticular bodies differentiate into elementary bodies which are released from the cell to continue the infection. N. gonorrhoeae are facultative intracellular bacteria, and T. p. pallidum are highly motile spirochaetes which can move between the cells to aid dissemination. All three pathogens are difficult to culture: C. trachomatis through its intracellular nature and requirement for tissue culture, N. gonorrhoeae through its fastidious nature and specific nutritional requirements [12], and T. p. pallidum which has not been successfully cultured in vitro and must be propagated in a rabbit host [13▪]. As these bacteria naturally only infect humans, suitable animal models of these diseases do not exist.

FIGURE 1

FIGURE 1

Back to Top | Article Outline

INFORMATION GAINED FROM GENOMIC STUDIES

Until recently, there were very few genomes of bacterial STIs available, in contrast to the number of other bacterial genomes sequenced [currently over 16 000 (http://www.genomesonline.org)]. This is despite their importance to public health: complications associated with chlamydia in the UK are estimated to cost £100 million annually (www.chlamydiascreening.nhs.uk) and some gonorrhoea strains have emerged that are resistant to all treatment antibiotics.

Genomics has helped to open a window into parts of the biology that were previously inaccessible. Particularly in the cases of C. trachomatis and T. p. pallidum, very little was known about the genetics of these organisms because of a lack of molecular tools and the inability to grow them outside cell culture or the host. All three of these STI pathogens have small genomes of 1.0–2.2 Mb, encoding only 889–2662 genes (Table 1). The genomes of C. trachomatis and T. p. pallidum appear to have undergone genome degradation, losing many of the genes required to grow independently of the host. This process is known as reductive evolution and is usually associated with specialization to a new, isolated niche with a narrow ecological spectrum. All three bacteria also contain large families of outer membrane proteins, which may be associated with immune evasion (Table 1) [4,8,9].

Back to Top | Article Outline

Chlamydia trachomatis

The first forays into C. trachomatis genomics generated reference genomes for the three disease-causing types (pathotypes): urogenital, trachoma and LGV [4,5,14]. Comparative analyses of these small genomes (1.0 Mb) found that all possess the same gene order along the chromosome (synteny). The high sequence conservation, with 846 genes in common and few or no true whole-gene differences [5], indicates that only subtle differences must determine the disease phenotype. Variable genes can provide clues to the differences between pathotypes: these include a cytotoxin gene within the region of the genome called the plasticity zone [15] which is largely degraded in all C. trachomatis genomes, but may retain some activity within urogenital strains [16,17], and genes encoding tryptophan synthase which are inactivated in trachoma strains [14]. This enzyme converts indole, found in the genital tract, to tryptophan, which is otherwise degraded through an immune trigger [4,18,19]. Additionally, all strains possess an almost identical cryptic plasmid of 7.5 kb.

C. trachomatis genomics has recently moved towards large-scale, population-based sequencing projects, with 66 genomes now sequenced covering temporal and geographic diversity [6,20▪▪,21–24]. These studies confirm the high similarity between genomes, with only 7616 base changes or single-nucleotide polymorphisms (SNPs) separating urogenital and LGV strains (Table 1). Phylogenetic analysis of the data shows us that the LGV strains form a separate clade exhibiting low diversity, with the STI strains split into two clades separated by 5509 SNPs, and the ocular strains branching from one of these clades (Fig. 2) [20▪▪]. The most surprising finding in the analysis of these genomes was the extent of recombination apparent between strains of C. trachomatis [20▪▪]. Although full recombination machinery was identified within the first genome sequence [4], it was thought that the barriers for recombination were too high because of the intracellular nature of this pathogen. However, these studies have shown that recombination is rife, even between pathotypes associated with different anatomical sites, a finding which has major implications for our understanding of chlamydial biology and epidemiology.

FIGURE 2

FIGURE 2

Back to Top | Article Outline

Neisseria gonorrhoeae

Four genome sequences of N. gonorrhoeae (2.2 Mb) are available for analysis [7,25,26], the most divergent strains being separated by 7331 SNPs (Table 1); a further 14 genomes exist in draft form (http://www.broadinstitute.org/). N. gonorrhoeae is naturally competent and able to take up exogenous DNA [27] which can be incorporated and used to shuffle novel functions into its genome. Specialized 10–12 bp repeat elements called DNA uptake sequences (DUSs) [28] are present at high density (over 1900 copies) throughout the genome. Recipient bacteria actively recognize DUSs in free DNA, bind them and import the DNA, involving Type IV pili which are also used in bacterial motility [29]. The canonical N. gonorrhoeae DUSs are found in closely related commensal and pathogenic Neisseria species including Neisseria meningitidis that also inhabit human mucosal surfaces, providing an ideal opportunity for genetic exchange [30]. Indeed regions of apparent recombination have been identified in the genome of strain SM-3, associated with transfer of antibiotic resistance determinants [26]. A range of plasmids are associated with the strains of N. gonorrhoeae, from the small cryptic plasmid of 4.2 kb to larger conjugative plasmids which promote their own transfer between strains and may carry determinants of antibiotic resistance [8].

Back to Top | Article Outline

Treponema pallidum subsp. pallidum

All treponemes, of which T. p. pallidum is one subspecies, have reduced, highly conserved genomes (1.1 Mb), despite significant differences in their host preference and clinical manifestations [31▪]. A comparison of the four sequenced T. p. pallidum genomes [9,32–35] shows that only 327 SNPs differentiate them (excluding hypervariable regions [35]). Much of the variation lies within the specific regions including the gene encoding the acidic repeat protein (arp) and the trpD and trpK genes [36], and there is also evidence of intrastrain gene conversion of variable (V) regions within trpK during infection [37]. Key genes encoding the flagellar structural proteins enabling the characteristic spiralling motility have been identified, along with 13 genes involved in chemotaxis.

Back to Top | Article Outline

GENOMICS IN EPIDEMIOLOGY

Molecular epidemiological typing is often used for finer resolution of bacterial strain identity in epidemiological studies. For C. trachomatis and N. gonorrhoeae, there are several gene or repeat-based typing schemes [38,39,40▪]. If the aim is macroepidemiological, following long-term or global trends, multilocus sequence typing (MLST) schemes are often suitable [41–44], using a set of stable relatively conserved, slowly evolving and evolutionary more neutral housekeeping genes, distributed throughout the genome [40▪,45]. On the other hand, if the study is looking at community epidemics, local outbreaks or contact tracing over a short timescale, microepidemiological high-resolution schemes which focus on hypervariable regions of the genome are preferable [40▪,45]. These include multiple-locus variable number tandem repeat analysis (MLVA) and multilocus sequence analysis (MLSA) in C. trachomatis [38,46] and N. gonorrhoeae multiantigen sequence typing (NG-MAST) [47]. The most common typing technique in T. p. pallidum [48] was developed using the number of repeats in arp and restriction fragment length polymorphism (RFLP) analysis of trp genes [49].

The most widely used typing scheme in Chlamydia is ompA genotyping, based on the gene encoding the major outer membrane protein (MOMP), with genotypes reflecting tropism: ocular A–C, urogenital D–K and LGV L1–L3. Global studies show that the most common urogenital genotypes are E, F and D, leading to the common notion that over the last few decades the overall populations of urogenital C. trachomatis genotypes has been relatively stable. Until recently, this nomenclature has been the only method available to predict relationships between isolates and to perform association studies. Such studies looking for associations between genotype and age, sex, number of sexual partners or clinical symptoms are divided as to whether there is a significant link [50–55].

In the light of whole-genome phylogenies (Fig. 2) and ongoing recombination, we can no longer infer strain relatedness from ompA genotype. The ompA gene has been found to undergo recombination, and the same ompA genotype can exist on the unrelated branches of the C. trachomatis phylogenetic tree [20▪▪]. This may explain why C. trachomatis genotypes appear epidemiologically static, as genomic flux is masked by the ompA genotype, and associations with disease or demographic cannot be determined. It also explains why all the existing gene-based C. trachomatis typing schemes can give conflicting results with the underlying whole-genome phylogeny and with each other (Fig. 3).

FIGURE 3

FIGURE 3

In contrast to other human pathogens [56–60], the use of whole-genome sequencing for the epidemiological investigation of bacterial STIs has hardly begun. What we have learnt so far has rephrased what we thought we knew about the prevalence and spread of C. trachomatis worldwide. If we are truly to understand both the local and global epidemiology of bacterial STIs, we must go back to the beginning. Using genomic methods, we can gain an understanding of the baseline variation within the pathogen population, providing us with information regarding how these bacteria evolve, acquire antibiotic resistance and cause outbreaks.

Back to Top | Article Outline

ADVANCES IN DIAGNOSIS

Diagnosis has historically involved microscopy (chlamydia, gonorrhoea and syphilis), growth (chlamydia and gonorrhoea) and serology (chlamydia and syphilis). For greater speed, throughput, sensitivity and specificity, nucleic acid amplification tests (NAATs) are currently the gold standard for chlamydia and gonorrhoea in well resourced settings.

Two recent cases emphasize how caution must be used in the choice of diagnostic targets. Previously, two of the main commercial C. trachomatis NAATs used a single target on the multicopy cryptic plasmid. However, a deletion of 377 bp covering the target site for both NAATs led to the emergence of a new strain which gave a false-negative diagnostic result and so went untreated, being passed between infected individuals without their knowledge, before being recognized in Sweden in 2006 [61]. From genomic and phenotypic studies, it became apparent that the deletion of the 377 bp and consequent inactivation of a plasmid gene did not impact negatively on the growth or virulence of the strain [6,22], instead giving a huge advantage in being able to propagate under the diagnostic radar. The redesigned NAATs for C. trachomatis diagnosis from these manufacturers now use dual targets.

Diagnostic-driven evolution is clearly a phenomenon to be aware of. The porA gene in N. gonorrhoeae is a pseudogene used as a diagnostic target in several commercial and in-house NAATs, whereas the closely related N. meningitidis (Fig. 1) has an intact porA gene with a substantially different sequence, and commensal Neisseria strains have no porA gene. Four N. gonorrhoeae isolates, belonging to different clonal lineages, have been found in Australia, Scotland and Sweden which appear to have gained the porA gene from N. meningitidis, again becoming diagnostically ‘invisible’ [62,63,64▪▪]. These strains were identified through culture of the samples and use of additional diagnostic methods, but the extent of the spread of these clones remains unknown. In this case also, dual target NAATs would increase sensitivity and specificity.

These examples highlight a major public health issue, telling us that diagnostic targets must be carefully chosen and constantly monitored. On a population level, the lack of treatment following a negative NAAT provides a strong Darwinian selective pressure on the bacterial community by removing, through antibiotic treatment, only those isolates providing a positive test result. An understanding of how the genomes of these bacteria evolve is essential if we are to reduce the likelihood of future ‘diagnostic escapes’.

Back to Top | Article Outline

ANTIMICROBIAL RESISTANCE

Treatment failure because of antibiotic resistance is a serious threat to human health for many bacterial pathogens. The increasing use of NAATs for STI diagnostics is a worrying trend; culture-based techniques are being eliminated leading to a dearth of live strains for resistance testing. This is compounded by a lack of routine test-of-cure, meaning it is impossible to distinguish treatment failure from reinfection. Although known genetic mechanisms of resistance can be tested through NAATs, novel or obscure resistance mechanisms are recalcitrant to this approach, and correlation with treatment outcome is not absolute.

N. gonorrhoeae has a history of acquiring or developing resistance to antibiotics, including all first-line treatment drugs such as sulphonamides, penicillins, tetracyclines, macrolides, fluoroquinolones and recently cephalosporins [65▪,66]. The resistance mechanisms may involve mutations in chromosomal targets, efflux systems or acquisition of novel genes by transformation or plasmid-mediated conjugation [65▪,67–69]. Most recently, chromosomal mosaic penA genes have been identified, conferring resistance to extended-spectrum cephalosporins including ceftriaxone and cefixime and threatening us with the development of an untreatable ‘superbug’ [65▪].

Syphilis has not yet developed resistance to its treatment antibiotic penicillin. However, two mutations conferring resistance to macrolides have been identified [70,71], possibly indirectly selected as a result of using azithromycin to treat other STIs and ‘genital discharge syndromes’ [72]. Similarly, there is no evidence that C. trachomatis, treated in most cases with a single dose of azithromycin, has developed resistance, although resistance to several antibiotics has been reported in vitro [73▪▪,74,75]. For both chlamydia and syphilis, there are no internationally agreed standard methods to assess minimum inhibitory concentrations in vitro [76], and assessment of antibiotic resistance relies on the identification of treatment failures.

Back to Top | Article Outline

CONCLUSION

Genome sequence data is essential for understanding the biology, pathogenesis, virulence and epidemiology of these pathogens, particularly those whose study is intractable by other means. For known recombinogenic bacteria such as C. trachomatis and N. gonorrhoeae, accurate whole-genome sequences are the ultimate typing tool. Genome sequencing is becoming faster, cheaper, more high throughput and more available, meaning that genomic epidemiology can now be performed within real-time clinical situations [11,59,77–83]. Combined with a growing body of genomic data, it is hoped that recent advances in the genetic manipulation of C. trachomatis [73▪▪,84] will allow further investigations into chlamydia genetics, building on the output of comparative genomics.

Back to Top | Article Outline

Acknowledgements

The authors thank Magnus Unemo for useful discussions in the preparation of this manuscript. This work was supported by the Wellcome Trust (grant number 098051).

Back to Top | Article Outline

Conflicts of interest

There are no conflicts of interest.

Back to Top | Article Outline

REFERENCES AND RECOMMENDED READING

Papers of particular interest, published within the annual period of review, have been highlighted as:

  • ▪ of special interest
  • ▪▪ of outstanding interest

Additional references related to this topic can also be found in the Current World Literature section in this issue (p. 103).

Back to Top | Article Outline

REFERENCES

1. WHO. Global incidence and prevalence of selected curable sexually transmitted infections – 2008. Geneva: World Health Organisation; 2012.
2. Health Protection Agency UK. Sexually transmitted infections in England, 2011. Vol. 6. UK: Health Protection Agency; 2012.
3. Prevention CfDCa. Sexually transmitted disease surveillance 2010. Atlanta, USA: U.S. Department of Health and Human Services; 2011.
4. Stephens RS, Kalman S, Lammel C, et al. Genome sequence of an obligate intracellular pathogen of humans: Chlamydia trachomatis. Science 1998; 282:754–759.
5. Thomson NR, Holden MT, Carder C, et al. Chlamydia trachomatis: genome sequence analysis of lymphogranuloma venereum isolates. Genome Res 2008; 18:161–171.
6. Unemo M, Seth-Smith HMB, Cutcliffe LT, et al. The Swedish new variant of Chlamydia trachomatis: genome sequence, morphology, cell tropism and phenotypic characterization. Microbiology 2010; 156:1394–1404.
7. Chung GT, Yoo JS, Oh HB, et al. Complete genome sequence of Neisseria gonorrhoeae NCCP11945. J Bacteriol 2008; 190:6035–6036.
8. Snyder LAS, Davies JK, Ryan CS, Saunders NJ. Comparative overview of the genomic and genetic differences between the pathogenic Neisseria strains and species. Plasmid 2005; 54:191–218.
9. Fraser CM, Norris SJ, Weinstock GM, et al. Complete genome sequence of Treponema pallidum, the syphilis spirochaete. Science 1998; 281:375–388.
10. WHO. Global WHO alliance for the elimination of blinding trachoma by 2020. In: Weekly Epidemiological Report. Vol. 17 (87). World Health Organisation; 2012. pp. 161–168.
11. Fournier PE, Raoult D. Prospects for the future using genomics and proteomics in clinical microbiology. Annu Rev Microbiol 2011; 65:169–188.
12. Catlin WB. Nutritional profiles of Neisseria gonorrhoeae, Neisseria meningitidis, and Neisseria lactamica in chemically defined media and the use of growth requirements for gonococcal typing. J Infect Dis 1973; 128:178–194.
13▪. Ho EL, Lukehart SA. Syphilis: using modern approaches to understand an old disease. J Clin Invest 2011; 121:4584–4592.

An elegant review of the syphilis bacterium.

14. Carlson JH, Porcella SF, McClarty G, Caldwell HD. Comparative genomic analysis of Chlamydia trachomatis oculotropic and genitotropic strains. Infect Immun 2005; 73:6407–6418.
15. Read TD, Myers GS, Brunham RC, et al. Genome sequence of Chlamydophila caviae (Chlamydia psittaci GPIC): examining the role of niche-specific genes in the evolution of the Chlamydiaceae. Nucleic Acids Res 2003; 31:2134–2147.
16. Belland RJ, Scidmore MA, Crane DD, et al. Chlamydia trachomatis cytotoxicity associated with complete and partial cytotoxin genes. Proc Natl Acad Sci 2001; 98:13984–13989.
17. Carlson JH, Hughes S, Hogan D, et al. Polymorphisms in the Chlamydia trachomatis cytotoxin locus associated with ocular and genital isolates. Infect Immun 2004; 72:7063–7072.
18. Caldwell HD, Wood H, Crane D, et al. Polymorphisms in Chlamydia trachomatis tryptophan synthase genes differentiate between genital and ocular isolates. J Clin Invest 2003; 111:1757–1769.
19. McClarty G, Caldwell HD, Nelson DE. Chlamydial interferon gamma immune evasion influences infection tropism. Curr Opin Microbiol 2007; 10:47–51.
20▪▪. Harris SR, Clarke IN, Seth-Smith HMB, et al. Whole-genome analysis of diverse Chlamydia trachomatis strains identifies phylogenetic relationships masked by current clinical typing. Nat Genet 2012; 44:364–366.

The largest comparative study of Chlamydia trachomatis genomes to date.

21. Jeffrey BM, Suchland RJ, Quinn KL, et al. Genome sequencing of recent clinical Chlamydia trachomatis strains identifies loci associated with tissue tropism and regions of apparent recombination. Infect Immun 2010; 78:2544–2553.
22. Seth-Smith HMB, Harris SR, Persson K, et al. Co-evolution of genomes and plasmids within Chlamydia trachomatis and the emergence in Sweden of a new variant strain. BMC Genomics 2009; 10:239.
23. Joseph SJ, Didelot X, Rithschild J, et al. Population genomics of Chlamydia trachomatis: insights on drift, selection, recombination, and population structure. Mol Biol Evol 2012; 29:3933–3946.
24. Somboonna N, Wan R, Ojcius DM, et al. Hypervirulent Chlamydia trachomatis clinical strain is a recombinant between lymphogranuloma venereum (L(2)) and D lineages. Mol Biol Evol 2011; 2:e00045–e00011.
25. Chen C-C, Hsia K-C, Huang C-T, et al. Draft genome sequence of a dominant, multidrug-resistant Neisseria gonorrhoeae strain, TCDC-NG08107, from a sexual group at high risk of acquiring human immunodeficiency virus infection and syphilis. J Bacteriol 2011; 193:1788–1789.
26. Hess D, Wu A, Golparian D, et al. Genome sequencing of a Neisseria gonorrhoeae isolate of a successful international clone 2 with decreased susceptibility/resistance to extended-spectrum cephalosporins. Antimicrob Agents Chemother 2012; 56:5633–5641.
27. Sparling PF. Genetic transformation of Neisseria gonorrhoeae to streptomycin resistance. J Bacteriol 1966; 92:1364–1371.
28. Graves JF, Biswas GD, Sparling PF. Sequence-specific DNA uptake in transformation of Neisseria gonorrhoeae. J Bacteriol 1982; 152:1071–1077.
29. Biswas GD, Sox T, Blackman E, Sparling PF. Factors affecting genetic transformation of Neisseria gonorrhoeae. J Bacteriol 1977; 129:983–992.
30. Marri PR, Paniscus M, Weyand NJ, et al. Genome sequencing reveals widespread virulence gene exchange among human Neisseria species. PLoS One 2010; 5:e11835.
31▪. Smajs D, Norris SJ, Weinstock GM. Genetic diversity in Treponema pallidum: implications for pathogenesis, evolution and molecular diagnostics of syphilis and yaws. Infect Genet Evol 2011; 12:191–202.

A clear review of syphilis genomics.

32. Čejková D, Zobanikova M, Chen L, et al. Whole genome sequences of three Treponema pallidum ssp. pertenue strains: yaws and syphilis treponemes differ in less than 0.2% of the genome sequence. PLoS Negl Trop Dis 2012; 6:e1471.
33. Giacani L, Chattopadhyay S, Centurion-Lara A, et al. Footprint of positive selection in Treponema pallidum subsp. pallidum genome sequences suggest adaptive microevolution of the syphilis pathogen. PLoS Negl Trop Dis 2012; 6:e1698.
34. Giacani L, Jeffrey BM, Molini BJ, et al. Complete genome sequence and annotation of the Treponema pallidum subsp. pallidum Chicago strain. J Bacteriol 2010; 192:2545–2546.
35. Matejkova P, Strouhal M, Smajs D, et al. Complete genome sequenced of Treponema pallidum ssp. pallidum strain SS14 determined with oligonucleotide arrays. BMC Microbiol 2008; 8:76.
36. Mikalova L, Strouhal M, Cejkova D, et al. Genome analysis of Treponema pallidum subsp. pallidum and subsp. pertenue strains: most of the genetic differences are localised in six regions. PLoS One 2010; 5:e15713.
37. Centurion-Lara A, LaFond RE, Hevner K, et al. Gene conversion: a mechanism for generation of heterogeneity in the tprK gene of Treponema pallidum during infection. Mol Microbiol 2004; 52:1579–1596.
38. Pedersen LN, Herrman B, Moller JK. Typing Chlamydia trachomatis: from egg yolk to nanotechnology. FEMS Immunol Med Microbiol 2009; 55:120–130.
39. Thomson NR, Clarke IN. Chlamydia trachomatis: small genome, big challenges. Future Microbiol 2010; 5:555–561.
40▪. Unemo M, Dillon J-AR. Review and International Recommendation of methods for typing Neisseria gonorrhoeae isolates and their implications for improved knowledge of gonococcal epidemiology,treatment, and biology. Clin Microbiol Rev 2011; 24:447–458.

This is a clear and detailed overview of typing in Neisseria gonorrhoeae.

41. Dean D, Bruno WJ, Wan R, et al. Predicting phenotype and emerging strains among Chlamydia trachomatis infections. Emerg Infect Dis 2009; 15:1385–1394.
42. Maiden MCJ, Bygraves JA, Feil E, et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci 1998; 95:3140–3145.
43. Pannekoek Y, Morelli G, Kusecek B, et al. Multi locus sequence typing of Chlamydiales: clonal groupings within the obligate intracellular bacteria Chlamydia trachomatis. BMC Microbiol 2008; 8:42.
44. Viscidi RP, Demma JC. Genetic diversity of Neisseria gonorrhoeae housekeeping genes. J Clin Microbiol 2003; 41:197–204.
45. Ikryannikova LN, Shkarupeta MM, Shitikov EA, et al. Comparative evaluation of new typing schemes for urogenital Chlamydia trachomatis isolates. FEMS Immunol Med Microbiol 2010; 59:188–196.
46. Klint M, Fuxelius HH, Goldkuhl RR, et al. High-resolution genotyping of Chlamydia trachomatis strains by multilocus sequence analysis. J Clin Microbiol 2007; 45:1410–1414.
47. Martin IMC, Ison CA, Aanensen DM, et al. Rapid sequence-based identification of gonococcal transmission clusters in a large metropolitan area. J Infect Dis 2004; 189:1497–1505.
48. Peng R-R, Wang AL, Li J, et al. Molecular typing of Treponema pallidum: a systematic review and meta-analysis. PLoS Negl Trop Dis 2011; 5:e1273.
49. Pillay A, Liu H, Chen CY, et al. Molecular subtying of Treponema pallidum subspecies pallidum. Sex Transm Dis 1998; 25:408–414.
50. Millman K, Black CM, Johnson RE, Dean D. Population-based genetic and evolutionary analysis of Chlamydia trachomatis urogenital strain variation in the United States. J Bacteriol 2004; 186:2457–2465.
51. Gao X, Chen X-S, Yin Y-P, et al. Distribution study of Chlamydia trachomatis serovars among high-risk women in China performed using PCR–restriction fragment length polymorphism genotyping. J Clin Microbiol 2007; 45:1185–1189.
52. Van de Laar MJ, van Duynhoven YT, Fennema JS, et al. Differences in clinical manifestations of genital chlamydial infections related to serovars. Genitourin Med 1996; 72:261–265.
53. Machado ACS, Bandea CI, Alves MFC, et al. Distribution of Chlamydia trachomatis genovars among youths and adults in Brazil. J Med Microbiol 2010; 60:472–476.
54. Lysen M, Osterlund A, Rubin C-J, et al. Characterization of ompA genotypes by sequence analysis of DNA from all detected cases of Chlamydia trachomatis infections during 1 year of contact tracing in a Swedish County. J Clin Microbiol 2004; 42:1641–1647.
55. Van Duynhoven YT, Ossewaarde JM, Derksen-Nawrocki RP, et al. Chlamydia trachomatis genotypes: correlation with clinical manifestations of infection and patients’ characteristics. Clin Infect Dis 1998; 26:314–322.
56. Croucher NJ, Harris SR, Fraser CM, et al. Rapid pneumococcal evolution in response to clinical interventions. Science 2011; 331:430–434.
57. Gardy JL, Johnston JC, Ho Sui SJ, et al. Whole-genome sequencing and social-network analysis of a tuberculosis outbreak. N Engl J Med 2011; 364:730–739.
58. Harris SR, Feil EJ, Holden MTG, et al. Evolution of MRSA during hospital transmission and intercontinental spread. Science 2010; 327:469–474.
59. Lewis T, Loman NJ, Bingle L, et al. High-throughput whole-genome sequencing to dissect the epidemiology of Acinetobacter baumannii isolates from a hospital outbreak. J Hosp Infect 2010; 75:37–41.
60. Mutreja A, Kim DW, Thomson NR, et al. Evidence for several waves of global transmission in the seventh cholera pandemic. Nature 2011; 477:462–465.
61. Ripa T, Nilsson P. A variant of Chlamydia trachomatis with deletion in cryptic plasmid: implications for use of PCR diagnostic tests. Euro Surveill 2006; 9:E061109.061102.
62. Eastick K, Winter A, Jamdar S. Identification of Neisseria gonorrhoeae isolates with a recombinant porA gene in Scotland, United Kingdom 2010 to 2011. Euro Surveill 2012; 17:20101.
63. Golparian D, Johansson E, Unemo M. Clinical Neisseria gonorrhoeae isolate with a N. meningitidis porA gene and no prolyliminopeptidase activity, Sweden, 2011 – danger of false-negative genetic and culture diagnostic results. Euro Surveill 2012; 17:20102.
64▪▪. Whiley DM, Limnios A, Moon NJ, et al. False-negative results using Neisseria gonorrhoeae porA pseudogene PCR – a clinical gonococcal isolate with an N. meningitidis porA sequence, Australia. 2011; 16:2.

This is the first description of a strain of Neisseria gonorrhoeae containing porA from Neisseria meningitidis.

65▪. Unemo M, Shafer WM. Antibiotic resistance in Neisseria gonorrhoeae: origin, evolution and lessons learned for the future. Ann N Y Acad Sci 2011; 1230:E19–E28.

A review of the history of antibiotic resistance in Neisseria gonorrhoeae.

66. Lewis DA, Lukehart SA. Antimicrobial resistance in Neisseria gonorrhoeae and Treponema pallidum: evolution, therapeutic challenges and the need to strengthen global surveillance. Sex Transm Infect 2011; 87:ii39–ii43.
67. Fayemiwo SA, Muller EE, Gumede L, Lewis DA. Plasmid-mediated penicillin and tetracycline resistance among Neisseria gonorrhoeae isolates in South Africa: prevalence, detection and typing using a novel molecular assay. Sex Transm Dis 2011; 38:329–333.
68. Goire N, Sloots TP, Nissen MD, Whiley DM. Protocol for the molecular detection of antibiotic resistance mechanisms in Neisseria gonorrhoeae. Methods Mol Biol 2012; 903:319–328.
69. Kugelman G, Tapsall JW, Goire N, et al. Simple, rapid, and inexpensive detection of Neisseria gonorrhoeae resistance mechanisms using heat-denatured isolates and SYBR Green-based Real-Time PCR. Antimicrob Agents Chemother 2009; 53:4211–4216.
70. Matejkova P, Flasarova M, Zakoucka H, et al. Macrolide treatment failure in a case of secondary syphilis: a novel A2059G mutation in the 23S rRNA gene of Treponema pallidum subsp. pallidum. J Med Microbiol 2009; 58:832–836.
71. Stamm LV, Bergen HL. A point mutation associated with bacterial macrolide resistance is present in both 23S rRNA genes of an erythromycin-resistant Treponema pallidum clinical isolate. Antimicrob Agents Chemother 2000; 44:806–807.
72. Muller EE, Paz-Bailey G, Lewis DA. Macrolide resistance testing and molecular subtyping of Treponema pallidum strains from Southern Africa. Sex Transm Infect 2012; 88:470–474.
73▪▪. Wang Y, Kahane S, Cutcliffe LT, et al. Development of a transformation system for Chlamydia trachomatis: restoration of glycogen biosynthesis by acquisition of a plasmid shuttle vector. PLoS Pathog 2011; 7:e1002258.

The first genetic transformation of Chlamydia trachomatis.

74. DeMars R, Weinfurter J, Guex E, et al. Lateral gene transfer in vitro in the intracellular pathogen Chlamydia trachomatis. J Bacteriol 2007; 189:991–1003.
75. Suchland RJ, Sandoz KM, Jeffrey BM, et al. Horizontal transfer of tetracycline resistance among Chlamydia spp. in vitro. Antimicrob Agents Chemother 2009; 53:4604–4611.
76. Norris SJ, Cox DL, Weinstock GM. Biology of Treponema pallidum: correlation of functional activities with genome sequence data. J Mol Microbiol Biotechnol 2001; 3:37–62.
77. Didelot X, Bowden R, Wilson DJ, et al. Transforming clinical microbiology with bacterial genome sequencing. Nat Rev Genet 2012; 13:601–612.
78. Eyre DW, Golubchik T, Gordon NC, et al. A pilot study of rapid benchtop sequencing of Staphylococcus aureus and Clostridium difficile for outbreak detection and surveillance. BMJ Open 2012; 2:e001124.
79. Köser CU, Ellington MJ, Cartwright EJP, et al. Routine use of microbial whole genome sequencing in diagnostic and public health microbiology. PLoS Pathog 2012; 8:e1002824.
80. Köser CU, Holden MT, Ellington MJ, et al. Rapid whole-genome sequencing for investigation of a neonatal MRSA outbreak. N Engl J Med 2012; 366:2267–2275.
81. Pallen M, Loman N. Are diagnostic and public health bacteriology ready to become branches of genomic medicine? Genome Med 2011; 3:53.
82. Parkhill J, Wren BW. Bacterial epidemiology and biology – lessons from genome sequencing. Genome Biol 2011; 12:230.
83. Snitkin ES, Zelazny AM, Thomas PJ, et al. Tracking a hospital outbreak of carbapenem-resistant Klebsiella pneumoniae with whole-genome sequencing. Sci Transl Med 2012; 4:148ra116.
84. Kari L, Goheen MM, Randall LB, et al. Generation of targetted Chlamydia trachomatis null mutants. Proc Natl Acad Sci 2011; 108:7189–7193.
Keywords:

chlamydia; diagnosis; epidemiology; genomics; gonorrhoea; syphilis; typing

Copyright © 2013 Wolters Kluwer Health, Inc. All rights reserved.